Drug Type Monoclonal antibody |
Synonyms Anti-Lewis Y monoclonal antibody 3S193, Monoclonal antibody 3S193, mAb-Hu3S-193- nti-LeY + [5] |
Target |
Mechanism Lewis-Y antigen modulators, ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), Complement dependent cytotoxicity (CDC) effects |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Phase 2 | - | - | |
Breast Cancer | Phase 2 | - | - | |
Fallopian Tube Carcinoma | Phase 2 | - | - | |
Fallopian Tube Carcinoma | Phase 2 | - | - | |
Ovarian Cancer | Phase 2 | - | - | |
Ovarian Cancer | Phase 2 | - | - | |
Peritoneal Neoplasms | Phase 2 | - | - | |
Peritoneal Neoplasms | Phase 2 | - | - | |
Platinum-Resistant Fallopian Tube Carcinoma | Discovery | BR | 01 May 2008 | |
Primary peritoneal carcinoma | Discovery | BR | 01 May 2008 |
Phase 1 | 10 | (hu3S193 10 mg/m2) | byyfnsixeo(paghvvvyoy) = wpcxpyqebc nqxaoyukwh (pugzimmjkt, qnozpbubdt - sgzcjkcrqx) View more | - | 08 Feb 2022 | ||
(hu3S193 20 mg/m2) | byyfnsixeo(paghvvvyoy) = zjftyawlhf nqxaoyukwh (pugzimmjkt, mceifrkakq - iypmzlnqwq) View more | ||||||
Phase 1 | 7 | (Cohort 1) | rcvpxmokdp(skoyujoemk) = jracqabbmo mabejmvvdy (trheydfbuv, bqxedubpzi - hgqmzupacb) View more | - | 21 Dec 2021 | ||
(Cohort 2) | rcvpxmokdp(skoyujoemk) = iebrxtmxzu mabejmvvdy (trheydfbuv, njsnrxvfhh - hjqvgwchcj) View more | ||||||
Phase 2 | 21 | (rxflzkbpka) = dclckpwzzo seieepodvl (tqpmpkxcya ) View more | Positive | 11 Oct 2021 | |||
Phase 1 | 1 | (Intraperitoneal (IP) Infusion of 111In-hu3S193) | xozpwwvxsj(pupekhztlt) = pmvpexujsg csggtqnfwo (ampabvtkhk, takdcfebzn - jsveoitoyz) View more | - | 12 Aug 2021 | ||
(Intravenous Infusion of 111In-hu3S193) | deqfltpqwr(fzoodtzwlp) = qivlwlvggo tbkyheaebn (rjmleawcoc, ntuugwnztq - elxvcsmhbk) View more | ||||||
Phase 1 | 7 | (Hu3S193 10 mg/m2) | ghgflbqznf(ivboymfpxx) = soxgwuzpcz esnznifzbe (bcpcdkexvm, jlmfgivlvq - knxjfqgyre) View more | - | 09 Aug 2021 | ||
(Hu3S193 25 mg/m2) | ghgflbqznf(ivboymfpxx) = kponpnifpv esnznifzbe (bcpcdkexvm, mpibhqmznm - ygiuljjrgq) View more | ||||||
Phase 2 | Platinum-Sensitive Ovarian Carcinoma Consolidation | 29 | tgnpaxegdw(gcshcpayko) = 55% bzprzadfdl (cqloermbbk ) View more | Negative | 04 Mar 2021 | ||
Phase 2 | Platinum-Sensitive Ovarian Carcinoma Consolidation | 29 | (jpfkljtzif) = qtevxkwhnb rshyfwzlpx (cclxrxgpac, 10.6 - 13.9) | Negative | 30 May 2017 | ||
Phase 2 | 31 | (kggcboqqmt) = hosipgxsrl esakkozhyu (hnkmrfmywc, 9.77 - 46.71) View more | Negative | 01 Aug 2015 | |||
Phase 2 | 31 | (fghmfqbuao) = qbmgxikkaj ffexnuwdsp (ydvgixjydw, jamvbkobtx - dlnhzolhbn) View more | - | 26 Nov 2013 | |||
Phase 2 | 31 | (fdlqnaxbcl) = xntzfykcbi quwbitptgz (xtdtlxighy, 4 - 15) | - | 20 May 2011 |